Loading clinical trials...
Loading clinical trials...
This is a Phase III, multicenter, global, open-label, single-arm, retreatment study of an investigational drug called galiximab in combination with an approved drug called rituximab in subjects with r...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Biogen
NCT06510361 · Lymphoma, Follicular Lymphoma, and more
NCT07226843 · Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, and more
NCT02750670 · Lymphoma, Non-Hodgkin's
NCT03417765 · Lymphoma, Non-Hodgkin's, Adult, Lymphoma, Hodgkin's, Adult
NCT00395967 · Multiple Myeloma, Lymphoma, Non-Hodgkin's
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions